How do chemotherapy and age affect physical performance in breast cancer patients over 12 months of treatment? Results from the UPBEAT Study (UPBEAT WF-97415)

被引：0

|

作者：

Bluethmann, Shirley

Levine, Beverly

Leitzelar, Brianna

Ansley, Katherine

Thomas, Alexandra

Avis, Nancy

Hundley, Gregory

Klepin, Heidi

Weaver, Kathryn

Lesser, Glenn

机构：

来源：

CANCER RESEARCH | 2024年 / 84卷 / 09期

关键词：

D O I：

10.1158/1538-7445.SABCS23-PO1-12-11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO1-12-11

引用

收藏

页数：2

相关论文

共 23 条

[21] Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients
Bernard-Marty, C
Mano, M
Paesmans, M
Accettura, C
Munoz-Bermeo, R
Richard, T
Kleiber, K
Cardoso, F
Lobelle, JP
Larismont, D
Piccart, MJ
Di Leo, A
ANNALS OF ONCOLOGY, 2003, 14 (05) : 693 - 698
[22] Second malignancies following adjuvant chemotherapy: 6-Year results from a Belgian randomized study comparing cyclophosphamide, methotrexate und 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients
Mross, K
STRAHLENTHERAPIE UND ONKOLOGIE, 2003, 179 (10) : 715 - 716
[23] Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients' preference for either combined endocrine therapy (exemestane plus everolimus) or immunochemotherapy (capecitabine plus bevacizumab) as first line treatment for advanced HR+/HER2-breast cancer
Kurbacher, C. M.
Soeling, U.
Hahn, A.
Chiabudini, M.
Maintz, C.
Rieger, L.
Falkenstein, J.
Runkel, E.
Potthoff, K.
Decker, T.
CANCER RESEARCH, 2019, 79 (04)